Society for Maternal-Fetal Medicine Statement: Clinical Considerations for the Prevention of Respiratory Syncytial Virus Disease in Infants
- Naima Joseph; Jeffrey Kuller; Judette Louis; Brenna Hughes
Access Resources
About
This statement from the Society for Maternal-Fetal Medicine focuses on preventing respiratory syncytial virus (RSV) in infants. It describes two main prevention methods: a vaccine given to pregnant women and a monoclonal antibody treatment for infants. The vaccine is recommended between 32 and 36 weeks of pregnancy, while the antibody is given to babies under eight months old during RSV season. Both options have benefits and risks, including concerns about preterm birth with the vaccine. Doctors should help parents choose the best method based on safety, availability, and personal preferences.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.